Consensus statement for non-estrogen-based treatments for menopausal symptoms

Abstract

Non-estrogen-based therapies can be used for the treatment of hot flushes, for symptoms of urogenital atrophy and for lack of sexual desire and/or fatigue not improved by estrogen treatments. Treatment choice should be based on up-to-date information and targeted to individual women’s needs. Non-hormonal therapies are useful particularly for women with estrogen-dependent disease such as breast and endometrial cancers.

Keywords

Breast cancer menopause non-hormonal therapies sexual desire urogenital atrophy

Get full access to this article

View all access options for this article.

References

Rada

Capurro

Pantoja

. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; 9: CD004923.

Lammerink

de Bock

Schröder

. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas 2012; 73: 265–268.

Sideras

Loprinzi

. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010; 8: 1171–1179.

Freeman

Samuel

Lin

. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 117: 1095–1104.

Sassarini

Lumsden

. Non-hormonal management of vasomotor symptoms. Climacteric 2013; 16(Suppl 1): 31–36.

Carroll

Kelley

. Use of antidepressants for management of hot flashes. Pharmacotherapy 2009; 29: 1357–1374.

Nelson

Vesco

Haney

. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057–2071.

Suvanto-Luukkonen

Koivunen

Sundstrom

. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomised, 9 month, placebo controlled, double blind study. Menopause 2005; 12: 18–26.

Kalay

Demir

Haberal

. Efficacy of citalopram on climacteric symptoms. Menopause 2007; 14: 223–229.

10.

LaCroix

Freeman

Larson

. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012; 73: 361–368.

11.

Ensrud

Joffe

Guthrie

. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012; 19: 848–855.

12.

Freeman

Guthrie

Caan

. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305: 267–274.

13.

Jin

Desta

Stearns

. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–39.

14.

Lash

Cronin-Fenton

Ahern

. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010; 49: 305–312.

15.

L'Espérance

Frenette

Dionne

. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 2013; 21: 1461–1474.

16.

Paroxetine 20 mg. Summary of product characteristics (last updated eMC: 24 August 2011), http://www.medicines.org.uk/emc/medicine/23046/SPC/Paroxetine+20mg+Tablets/ (2011, accessed 6 May 2014).

17.

Loprinzi

Kugler

Sloan

. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised, controlled trial. Lancet 2000; 356: 2059–2063.

18.

Evams

Pritts

Vittinghoff

. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomised, controlled trial. Obstet Gynecol 2005; 105: 161–166.

19.

Speroff

Gass

Constantine

. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomised controlled trail. Obstet Gynecol 2008; 111: 77–87.

20.

Pandya

Morrow

Roscoe

. Gabapentin for hot flashes in 420 women with breast cancer: a double-blind placebo controlled trial. Lancet 2005; 366: 818–824.

21.

Pop

Tanna

Pitkin

. Breast cancer patient case study – prescribing of gabapentin for vasomotor symptom control and supporting patient compliance/concordance. Maturitas 2009; 63: S53.

22.

Loprinzi

Qin

Balcueva

. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010; 28: 641–647.

23.

Clonidine 25 mcg. Summary of product characteristics (last updated eMC: 02 August 2012), http://www.medicines.org.uk/emc/medicine/21711/SPC (2012, accessed 6 May 2014).

24.

Pandya

Raubertas

Flynn

. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132: 788–793.

25.

Early and locally advanced breast cancer. Diagnosis and treatment. NICE Clinical Guideline 80. Quick reference guide, www.nice.org.uk/nicemedia/pdf/CG80QuickRefGuide/pdf (2009, accessed 6 May 2014).

26.

Kingsberg

Wysocki

Magnus

. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790–1799.

27.

Sinha

Ewies

. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 2013; 16: 305–312.

28.

Baumgart

Nilsson

Evers

. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013; 20: 162–168.

29.

Lindau

Schumm

Laumann

. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762–774.

30.

Tomlinson JM, Rees M and Mander T (eds). Sexual health and the menopause. London: RSM Press and British Menopause Society Publications, 2005.

31.

Wylie

. Sexuality and the menopause. J Br Men Soc 2006; 12: 149–152.

32.

Davis

van der Mooren

van Lunsen

. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomised, placebo controlled trail. Menopause 2006; 13: 387–396.

33.

Braunstein

Sundwell

Katz

. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomised, placebo controlled trial. Arch Intern Med 2005; 165: 1582–1589.

34.

Simon

Braunstein

Nachtigall

. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226–5233.

35.

Shifren

Davis

Moreau

. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NMI study. Menopause 2006; 13: 770–779.

36.

Testim 50 mg gel. Summary of product characteristics (last updated eMC: 25 July 2012), http://www.medicines.org.uk/emc/medicine/22159/SPC/Testim+Gel/ (2012, accessed 6 May 2014).

37.

Testogel 50 mg gel. Summary of product characteristics (last updated eMC: 15 June 2007), http://www.medicines.org.uk/emc/medicine/12391 (2007, accessed 6 May 2014).

38.

Livial 2.5 mg. Summary of product characteristics (last updated eMC: 18 November 2013), http://www.medicines.org.uk/emc/medicine/8552/SPC/Livial+2.5mg+tablets/ (2013, accessed 6 May 2014).

39.

Tibolone 2.5 mgm tablets. Public assessment report, MHRA, http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023754.pdf (2006, accessed 6 May 2014).